Passage Bio, Inc. (PASG)
After hours:
| Previous close | 1.1900 |
| Open | 1.1700 |
| Bid | 1.1300 x 100 |
| Ask | 1.2200 x 100 |
| Day's range | 1.1201 - 1.2325 |
| 52-week range | 0.5750 - 1.7900 |
| Volume | |
| Avg. volume | 301,932 |
| Market cap | 73.352M |
| Beta (5Y monthly) | 1.27 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.5300 |
| Earnings date | 05 Aug 2024 - 09 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.75 |
GlobeNewswirePassage Bio Announces Recipient of Third Annual Tachi Yamada Scholarship Award
PHILADELPHIA, May 21, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced Carrie Gordon, a sophomore at Drexel University, as the third recipient of its Tachi Yamada Scholarship award. The scholarship honors the legacy of Dr. Tachi Yamada, co-founder and former Chairman of the Passage Bio Board of Directors and is open to students enrolled in life sciences
ZacksAll You Need to Know About Passage Bio (PASG) Rating Upgrade to Buy
Passage Bio (PASG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- GlobeNewswire
Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
Updated interim data from the upliFT-D trial in FTD-GRN demonstrated that Dose 1 PBFT02 achieved consistent elevation of CSF progranulin at six months post-treatment in the two patients with longest follow-upCompleted dosing of Cohort 1 (n=5) in upliFT-D trial; on track to deliver 6-month safety and biomarker data from Cohort 1 in 2H 2024Plan to continue studying Dose 1 in Cohort 2 of upliFT-D trial; expect to initiate dosing by the end of 1H 2024, as plannedInitiated regulatory process with FDA
